Premium
Clinical efficacy and indication of acetazolamide treatment on sleep apnea syndrome
Author(s) -
Inoue Yuichi,
Takata Kokichi,
Sakamoto Izumi,
Hazama Hidebumi,
Kawahara Ryuzo
Publication year - 1999
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1046/j.1440-1819.1999.00551.x
Subject(s) - acetazolamide , medicine , uvulopalatopharyngoplasty , apnea , anesthesia , sleep apnea , hypopnea , apnea–hypopnea index , polysomnography
The efficacy and indication of acetazolamide treatment on patients with sleep apnea syndrome (SAS) were discussed from assessing the changes of polysomnographic findings with the treatment in 75 SAS patients. For the patients as a whole, respiratory disorder variables improved significantly during the treatment. However, the number of acetazolamide treatment responders who showed a decrease of apnea hypopnea index (AHI) to 50% or less of the pretreatment value numbered only 34 (45.3%). The lower values of body mass index and AHI in the responder group indicated that monotherapy with acetazolamide is the treatment choice only for mild SAS cases without obesity. However, combined treatment with acetazolamide and uvulopalatopharyngoplasty was thought to be beneficial for severe cases.